CFO Mark Saad's presentation on March 2, 2011

1. Cytori Therapeutics, Inc. Nasdaq: CYTX CitiBank Global Healthcare Conference March 2, 2011

2. Safe Harbor Statement This presentation may contain certain ‘forward-looking statements’. All statements, other than statements of historical fact, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future are forward-looking statements. Such statements are based upon certain assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. The forward-looking statements included in this presentation are also subject to a number of material risks and uncertainties. We caution investors not to place undue reliance on the forward-looking statements contained in this presentation. We would advise reading our annual report filed with the United States Securities and Exchange Commission on Form 10-K for a more detailed description of these risks.

3. Enabling Practice of Regenerative Medicine Real-time Access to a Patient’s Own Regenerative Cells Unique Source Syringe of Cells Point-of-Care System ≈1 Hour Regenerative Cells Derived from Adipose Tissue (Fat)

5. Multipotent cells

6. Endothelial cells

7. Vasc. smooth muscle cells

8. Tissue resident macrophages

9. Perivascular cells

10. Adipocytes

11. Multipotent cells

12. Endothelial cells

13. Vasc. smooth muscle cells

14. Tissue resident macrophages

16. Goal: Drive Cartridge Sales for Multiple Apps Cardiovascular Disease Plastic and Reconstructive Surgery 18K potential customers 1 consumable per day 6 mm + consumables/year Cell & Tissue Storage Open Op System: ID new “Apps” and Fuel Pipeline

18. Hospital-based device

19. Reside in OR, cath lab, or cell & tissue bank

20. Available for ADVANCE trial

21. Manufacturing expertise & service infrastructure

24. What is the status of the Acute MI Study?

28. Three arms: 20 MM cells, 30 MM cells, & placebo

29. Up to 35 centers

34. Submit application in H1 2011

36. Leverage ADVANCE trial sites

39. Currently approx. 40 NOGA Star systems

41. Celution: Discovering New Applications Selling systems to researchers to develop new “apps” Investigator-sponsored trials taking place worldwide Radiation injury SUI Liver Renal Malignant wounds Cardiomyopathy Vocal cord paralysis HIV therapy-induced soft tissue atrophy Others Link: Most indications involve restoring blood flow to damaged tissue Cytori to select most-promising applications to advance or commercialize

43. Moderate to severe Incontinence

44. Single treatment

45. All improved10 weeks Post-Celution Treatment Dr. Gotoh Nagoya, Japan

46. What is the relevance of the new breast reconstruction developments?

47. RESTORE Procedure for Breast Reconstruction ‘Cell-Enriched Graft’ Treatment not complete until reconstruction Hospital-based procedure and call point Limited options for lumpectomy patients Favorable reimbursement environment Cells: improve “ischemic” state $43 $73 $128 Cells Fat $163 $76 $126 Clinical Clinical Clinical Partner Partner Partner

49. 75% pt satisfaction on (12-mo)

50. Improvement in scar, pigmentation, symmetry and defect index (6-Mo):

51. 2.8 to 3.9 in ptassessment (0-5 scale)

52. 3.1 to 4.1 in phys. assessment (0-5 scale)Binary patient and physician satisfaction with treatment results at 6- and 12-months

55. Minimally invasive

58. Support patient awareness/education (www.cellreconstruct.eu)

60. Supplemental Product: PureGraft™ Natural Fill Optimizes fat graft prep Worldwide approval Complements Celution® (EU) Celution lead qualifier (EU) Stand-alone product in US Convert users to Celution® upon U.S. clearance Point-of-Entry: Building out US sales team (6 direct reps) Targets $1.7 bb dermal fill mkt 46K annual fat- grafting procedures in U.S. and growing

61. Supplemental Product: PureGraft™ Natural Fill Fat grafting is growing trend in plastic surgery Ideally suited for low cost consumer awareness campaign TV, print and radio outreach around customers Distributor model Sound Surgical is first in the US Multiple in Europe Minimal training requirements 1000 + shipped from Q2 2010 launch to YE 2010

62. When is the Olympus device available?

63. Celution One: Next Generation Product Commercially available in Europe in 2011 Hospital-based system First system installed for ADVANCE Recon Formula transfer price Cardiac Other Apps Manufacturing JV Commercial rights

64. How strong is the IP?

68. Create customer loyalty with quality product and service

70. Summary

72. Equity Raise (Oct. 10): $19.3 M

73. Strategic Equity (Dec. 10): $10 M investment from AstellasLong-term Debt: $20 million (GE/SVB/Oxford term loan) Shares Outstanding: 53 million as adjusted Revenue Growth 30

79. Know-how, first mover, and $250 mm invested $60 MM (pro forma) in cash as of 9/30/10 Upcoming catalysts to support sales and advance pipeline 32

80. Thank You